Skip to content
value.today
Spero Therapeutics, LLC logo

Spero Therapeutics, LLC

Total raised
$43 M
1 round on record
Latest round
$43 M
Mar 2017
First round on record
Mar 2017
Today
Went public
See the company page

Spero Therapeutics, LLC is listed today as Spero Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Spero Therapeutics, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$9 MPrivate placement after listing$2 to $10 million

Spero Therapeutics, LLC: Private sale, Nov 2022

Investors in this round

1 investor had bought by the notice of Nov 15, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Spero Therapeutics, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ankit Mahadevia · Executive Officer, Director
  • Kamal C. Hamed · Executive Officer
  • Satyavrat Shukla · Executive Officer
  • Tamara C. Joseph · Executive Officer
  • Timothy C. Keutzer · Executive Officer
  • Cynthia C. Smith · Director
  • Frank E. Thomas · Director
  • John C. Pottage, Jr. · Director
  • Kathleen C. Tregoning · Director
  • Milind Deshpande · Director
  • Patrick E. Vink · Director
  • Scott C. Jackson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Satyavrat Shukla, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 15, 2022. Read the notice at the SEC.

equitySEC
Jun 2021$40 MPrivate placement after listing$10 to $50 million

Spero Therapeutics, LLC: Private sale, Jun 2021

Investors in this round

1 investor had bought by the notice of Jul 14, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Spero Therapeutics, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ankit Mahadevia · Executive Officer, Director
  • Cristina E. Larkin · Executive Officer
  • David E. Melnick · Executive Officer
  • Satyavrat E. Shukla · Executive Officer
  • Tamara E. Joseph · Executive Officer
  • Timothy E. Keutzer · Executive Officer
  • Cynthia C. Smith · Director
  • Frank E. Thomas · Director
  • Jean-Francois Formela · Director
  • John C. Pottage, Jr. · Director
  • Milind Deshpande · Director
  • Patrick C. Vink · Director
  • Scott Jackson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Satyavrat Shukla, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 14, 2021. Read the notice at the SEC.

equitySEC
Mar 2017$43 MNo. 1$10 to $50 million

Spero Therapeutics, LLC: Raise no. 1, Mar 2017

Investors in this round

11 investors had bought by the notice of Mar 21, 2017: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Spero Therapeutics, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$43 M of $43 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Ankit Mahadevia · Executive Officer, Director
  • Stephen Garbacz · Executive Officer
  • Casper Breum · Director
  • Jean-Francois Formela · Director
  • Milind Deshpande · Director
  • Patrick Vink · Director
  • Reza Halse · Director
  • Vikas Goyal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ankit Mahadevia, M.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 21, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Spero Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration revenue - related party $47.03 million (70%), Collaboration revenue $12.59 million (19%), Grant Revenue $7.18 million (11%).

    Annual report (SEC XBRL) · Dec 2025

  • Spero Therapeutics, LLC chose not to state its revenue in its newest notice of a funding round (Nov 2022).

    SEC Form D · Nov 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2022

Products and services#

No products or services of Spero Therapeutics, LLC are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Spero Therapeutics, LLC
InvestorKindAmountRoundRoleSource
Alphabet Inc.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Atlas Venture Associates IX, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Atlas Venture Associates IX, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Atlas Venture Fund IX, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
GSK PLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
GV 2015 GP, L.L.C.Othernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
GV 2015, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Invest A/s LundbeckfondPersonnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.

Largest shareholders today

Institutions holding Spero Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Spero Therapeutics, LLC
NameRoleNamed in
Ankit MahadeviaExecutive officerNov 2022
Kamal C. HamedExecutive officerNov 2022
Satyavrat ShuklaExecutive officerNov 2022
Tamara C. JosephExecutive officerNov 2022
Timothy C. KeutzerExecutive officerNov 2022
Cristina E. LarkinExecutive officerJul 2021
David E. MelnickExecutive officerJul 2021
Satyavrat E. ShuklaExecutive officerJul 2021
Tamara E. JosephExecutive officerJul 2021
Timothy E. KeutzerExecutive officerJul 2021
Stephen GarbaczExecutive officerMar 2017
Ankit MahadeviaDirectorNov 2022
Cynthia C. SmithDirectorNov 2022
Frank E. ThomasDirectorNov 2022
John C. Pottage, Jr.DirectorNov 2022
Kathleen C. TregoningDirectorNov 2022
Milind DeshpandeDirectorNov 2022
Patrick E. VinkDirectorNov 2022
Scott C. JacksonDirectorNov 2022
Jean-Francois FormelaDirectorJul 2021
Patrick C. VinkDirectorJul 2021
Scott JacksonDirectorJul 2021
Casper BreumDirectorMar 2017
Patrick VinkDirectorMar 2017
Reza HalseDirectorMar 2017
Vikas GoyalDirectorMar 2017

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.